Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to browse AJSM online!

Sign In to gain access to subscriptions and/or personal tools.
Medical Decision Making
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ramsey, S. D.
Right arrow Articles by Nettleman, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramsey, S. D.
Right arrow Articles by Nettleman, M. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Cost - Effectiveness of Prophylactic AZT Following Neediestick Injury in Health Care Workers

Scott D. Ramsey

Mary D. Nettleman

In response to health care workers' concerns about contracting infection with the human immunodeficiency virus (HIV) in the workplace, several institutions now offer prophylactic azido-deoxythymidine (AZT) for needlesticks sustained while exposed to HIV-infected pa tients. The authors designed a model to evaluate the cost-effectiveness of AZT prophylaxis. If AZT were 100% effective, prophylaxis would cost $2,388 per life-year gained and $66,876 per life saved using a societal perspective. For each $100 increase in the cost of AZT, the cost per life-year saved increased $1,190. Reducing the efficacy of AZT to 75, 50, and 25% raised the costs per life-year gained to $3,184, $4,775, and $9,551, respectively If AZT were given for all needlesticks without regard to the HIV status of the source, the costs of prophylaxis would rise substantially. It is concluded that AZT, if moderately effective, can be cost-effective as a prophylactic agent but only if used in instances where the source is known to have an HIV infection. Key words. human immunodeficiency virus, azido-deoxy thymidine ; cost-effectiveness; needlesticks. (Med Decis Making 1992;12:142-148)

Medical Decision Making, Vol. 12, No. 2, 142-148 (1992)
DOI: 10.1177/0272989X9201200207


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Med Decis MakingHome page
J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst
A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Med Decis Making, December 1, 2007; 27(6): 789 - 821.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
S. D. Pinkerton, D. R. Holtgrave, and H. J. Pinkerton
Cost-effectiveness of Chemoprophylaxis After Occupational Exposure to HIV
Arch Intern Med, September 22, 1997; 157(17): 1972 - 1980.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
M. D. Nettleman, H. Geerdes, and M.-C. Roy
The Cost-effectiveness of Preventing Tuberculosis in Physicians Using Tuberculin Skin Testing or a Hypothetical Vaccine
Arch Intern Med, May 26, 1997; 157(10): 1121 - 1127.
[Abstract] [PDF]